Researchers from the Foundation The Royal Marsden NHS and the London Queen Mary University have developed an online calculator that can predict long-term risk of metastatic breast cancer.
Prognostic tool-CTS5 (evaluation of clinical treatment after 5 years), published in the Journal of Clinical Oncology, can be used to determine the risk of recurrence after standard hormone therapy. It can also predict which patients are low risk of relapse, so as not to undergo additional treatment and avoid adverse side effects.
Professor Mitch Dowsett, head of the Center for Breast Cancer Research, Professor of Biochemical Endocrinology Institute of Cancer Kyuzik Jack and Dr. Ivana Sestak of London Queen Mary University CTS5 developed after review of the data from two studies. Using a data set of previously published research, they counted the number of women who have appeared metastases in 5-10 years after completion of endocrine therapy. Then combined the data with information about the tumor, which was measured at the point of diagnosis, to produce CTS5 risk equation.
The researchers then tested the CTS5 on the data of the second study. It has been shown that CTS5 accurately divide the women into groups with low, medium or high risk of relapse after five years of hormonal therapy.
"The tool will help to improve clinical practice, benefitting patients with breast cancer and helping to avoid potentially unnecessary treatment," - says Professor Mitch Dowsett. After entering the patient data, including age, tumor size and tumor rate, the calculator shows the 5-10-year risk of relapse.
"Breast cancer is one of the few types of cancer that spread late relapse, and forecasting risk is especially important," - adds J. Kyuzik..
According to the researchers, more than 50 percent of women after hormonal treatment of cancer are at increased risk of metastasis. Online tool provides an easy way to get information about the risk of metastasis for every woman.
The authors point out that some of the data were taken from research that began over 20 years ago, and since then there have been treated with trastuzumab. Therefore, clinicians who treat this particular group, should be careful with the use of CTS5.